|1.||Macaulay, Valentine M: 10 articles (05/2011 - 05/2002)|
|2.||Macaulay, V M: 6 articles (11/2014 - 07/2001)|
|3.||Lee, Adrian V: 4 articles (01/2015 - 01/2009)|
|4.||Dong, Aiqiang: 4 articles (07/2012 - 01/2007)|
|5.||Kong, Minjian: 4 articles (07/2012 - 01/2007)|
|6.||Genua, Marco: 4 articles (01/2012 - 09/2007)|
|7.||Ludwig, Dale L: 4 articles (02/2011 - 05/2005)|
|8.||Lee, Ho-Young: 3 articles (06/2015 - 01/2011)|
|9.||Beltran, Pedro J: 3 articles (10/2014 - 05/2009)|
|10.||Ward, Colin W: 3 articles (01/2013 - 06/2004)|
08/27/2009 - "Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective in cancer treatment has been accumulating for almost two decades. "
05/20/2012 - "Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors."
01/01/2011 - "Naturally, a number of clinical trials have sought to directly abrogate insulin-like growth factor receptor 1 (IGF-1R) function and/or indirectly mitigate its downstream mediators such as mTOR, PI3K, MAPK, and others under the assumption that such therapeutic interventions would provide clinical benefit, demonstrable by impaired tumor growth as well as prolonged progression-free and overall survival for patients. "
04/01/2015 - "Type 1 insulin-like growth factor receptor (IGF-IR) signaling is often dysregulated in cancer. "
12/01/2014 - "However, compared with AH tumors, JH tumors grew several times faster, were more perfused, exhibited a two-fold higher mitotic index, and were more highly positive for insulin-like growth factor receptor phosphorylation. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
08/01/2014 - "A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer."
08/01/2011 - "Insulin-like Growth Factor Receptor 1 (IGF-1R) may play a role in the neoplastic progression of colorectal cancer because it is related to both cellular proliferation and differentiation. "
09/21/2006 - "Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer."
08/01/2014 - "Our objective was to assess tumor uptake of fluorodeoxyglucose by positron-emission tomography in patients with chemotherapy-refractory colorectal cancer treated with an anti-insulin-like growth factor receptor type 1 (anti-IGF-1R) monoclonal antibody, robatumumab. "
06/20/2015 - "Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo."
|3.||Breast Neoplasms (Breast Cancer)
09/01/2015 - "Inhibition of the type 1 insulin-like growth factor receptor (IGF1R) reduces the enhanced signaling, growth, and migration in breast tumor cells that occur upon REST loss. "
01/01/2015 - "Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer."
01/01/2015 - "Up to 50% of breast tumors express the activated form of the type 1 insulin-like growth factor receptor (IGF1R). "
01/01/2014 - "We sought to determine the level of protein expression of the critical components of the insulin-like growth factor receptor (IGFR) pathway and to evaluate their prognostic significance across the different early breast cancer subtypes. "
01/01/2014 - "Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes."
|4.||Wounds and Injuries (Trauma)
03/01/2001 - "The type 1 insulin-like growth factor receptor (IGF-IR) is effective in protecting cells from a variety of apoptotic injuries. "
03/11/1999 - "The type 1 insulin-like growth factor receptor (IGF-IR) is known to protect cells from a variety of apoptotic injuries. "
10/01/1999 - "The type 1 insulin-like growth factor receptor (IGF-1R), activated by its ligands, protects several cell types from a variety of apoptotic injuries. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/30/2015 - "According to previous reports demonstrating the implication of insulin-like growth factor receptor (IGF-1R) signaling in non-small cell lung cancer (NSCLC), in this study, the potential prognostic values of IGF-1R expression/activation were analyzed. "
09/15/2010 - "This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR) therapy. "
03/01/2010 - "The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). "
12/01/2015 - "The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have been increasingly recognized to drive the development of malignancies, including non-small cell lung cancer (NSCLC). "
01/01/2015 - "Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer."
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Messenger RNA (mRNA)
|6.||3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanol
|7.||Mitogen-Activated Protein Kinase Kinases (MEKs)
|8.||Small Interfering RNA (siRNA)
|9.||RNA (Ribonucleic Acid)
|10.||Insulin-Like Growth Factor I (IGF-1)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Molecular Targeted Therapy